CN1513862A - 车前草总苷的制备工艺及其在医药中的应用 - Google Patents
车前草总苷的制备工艺及其在医药中的应用 Download PDFInfo
- Publication number
- CN1513862A CN1513862A CNA021252548A CN02125254A CN1513862A CN 1513862 A CN1513862 A CN 1513862A CN A021252548 A CNA021252548 A CN A021252548A CN 02125254 A CN02125254 A CN 02125254A CN 1513862 A CN1513862 A CN 1513862A
- Authority
- CN
- China
- Prior art keywords
- total glycosides
- psyllium
- glycosides
- preparation
- psylliums
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 10
- 241001127637 Plantago Species 0.000 title description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 title 1
- 230000001882 diuretic effect Effects 0.000 claims abstract description 7
- 239000011347 resin Substances 0.000 claims abstract description 7
- 229920005989 resin Polymers 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 3
- 229930182470 glycoside Natural products 0.000 claims description 54
- 150000002338 glycosides Chemical class 0.000 claims description 53
- 241001499733 Plantago asiatica Species 0.000 claims description 52
- 235000003421 Plantago ovata Nutrition 0.000 claims description 51
- 239000009223 Psyllium Substances 0.000 claims description 38
- 229940070687 psyllium Drugs 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims description 11
- 229930185474 acteoside Natural products 0.000 claims description 9
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims description 9
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims description 9
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 239000002994 raw material Substances 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 238000010992 reflux Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- VUGRLRAUZWGZJP-UHFFFAOYSA-N Plantaginin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 VUGRLRAUZWGZJP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- VUGRLRAUZWGZJP-IAAKTDFRSA-N plantaginin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 VUGRLRAUZWGZJP-IAAKTDFRSA-N 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000961970 Plantago depressa Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- -1 benzyl carbinol glycosides compounds Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FNMHEHXNBNCPCI-QEOJJFGVSA-N Isoacteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](COC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H]1O FNMHEHXNBNCPCI-QEOJJFGVSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000263246 Plantago camtschatica Species 0.000 description 1
- 244000241113 Plantago maritima Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000721 basilar membrane Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- FNMHEHXNBNCPCI-RYEKTNFUSA-N isoacteoside Natural products C[C@@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](COC(=O)C=Cc3ccc(O)c(O)c3)O[C@@H](OCCc4ccc(O)c(O)c4)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O FNMHEHXNBNCPCI-RYEKTNFUSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
车前草总苷的制备工艺及其在医药中的应用提供了用含酸的低级醇为溶剂加热回流提取，再经大孔树脂纯化制备车前草总苷的生产工艺，制备车前草总苷胶囊、片剂、颗粒剂的处方及工艺，以及车前草总苷或制剂作为治疗慢性肾小球肾炎或/和作为免疫抑制或/和作为利尿剂在医药领域中的应用。
Description
技术领域 本发明属于中药技术应用领域，特征上涉及治疗慢性肾小球肾炎，和/或具有免疫抑制作用，和/或具有利尿作用。车前草总苷来源于常用中药平车前(Plantago depressaWilld)及其同属植物(如P.asiatica L.、P.camtschatica Link、P.maritima L等)的全草。
背景技术 慢性肾小球肾炎(chronic glomeralonephritis)是由多种疾病引起，通过不同的发病机理，具有不同病理改变，原发于肾小球的一组疾病。其临床特点为病程长，多为缓慢进行型。本病预后较差。慢性肾小球肾炎的治疗除利尿及降压等对症治疗外，目前临床治疗慢性肾小球肾炎的药物主要是糖皮质激素(如强的松)及细胞毒类(如盐酸氮芥、环磷酰胺)药物单独或联合使用，由于这些药物有明显的毒副作用，因此，临床迫切需要一种高效低毒的慢性肾小球肾炎治疗药物。
发明内容 本发明的目的是从车前草及其同属植物中提取的车前草总苷对慢性肾炎动物模型有明显降低尿蛋白作用，并有利尿作用，而未发现有明显的毒副作用。可以将它单独或与其他中西药合并研制成为一种慢性肾炎治疗剂。
车前草为车前科植物平车前Plantago depressa Willd的干燥全草，又称当道，始载于《四声本草》，性味甘、寒。归肝、肾、肺、小肠经。具有清热利尿、凉血解毒等功效。治小便不通、淋浊、尿血、水肿、痈肿疮毒、带下。车前草总苷含量为药材的0.5～6％，为苯乙醇苷类化合物，主要有acteoside(类叶升麻苷)、cisacteoside、isoacteoside、hydroxyacteoside、Methoxyacteoside等成分，其中主要成分acteoside，占总苷的40～70％。
本发明提供了一类如结构式I的化合物
结构式(I)
结构式(II)
本发明提供的车前草总苷的化学组成是一类以结构式(I)为骨架R1或为氢(H)或为羟基(OH)或为甲氧基(OCH3)取代，R2或为氢(H)或为结构式(II)取代，R3或为氢(H)或为结构式(II)取代，R4为鼠李糖基或为氢(H)取代的混合物。其中主要成分acteoside的结
构式是结构式(I)的R1、R2为氢取代，R3为结构式(II)取代，R4为鼠李糖基取代。
上述化合物的定量分析方法可以用常规方法进行，通常用色谱法。例如HPLC法；或用紫外分光光度法。
如上所述，本发明的总苷具有降低尿蛋白、利尿和改善血清肌肝和尿素氮水平等实际的治疗用途。
具体实施方式 实例1.车前草总苷的制备工艺
车前草粗粉，加入一定量的酸性醇，回流提取两次，滤过，合并两次滤液，减压回收醇至尽，水溶液离心除去沉淀后，通过大孔树脂柱，水洗，用20～80％的酸性醇洗脱，收集洗脱液减压回收醇至尽，水溶液再通过大孔树脂柱，水洗后，用60～100％的醇洗脱，收集洗脱液，加活性炭脱色，过滤，减压回收醇，得黄棕色车前草总苷。
实例2 车前草总苷的利尿作用试验
给大鼠1次灌胃给药，剂量为60mg/Kg和30mg/Kg，另设空白对照组(蒸馏水)，各组均按25ml/Kg的容量给予，同时腹腔注射生理盐水25ml/Kg(观察期间不再饮水)，然后置大鼠代谢笼，每笼放2只。记录1，2，3，4，6小时的尿量。3天后动物各组轮换再重复1次试验。可见，一次经口给予车前草总苷后尿量有增加，60mg/Kg组从给药后第一小时末开始至第六小时末的整个试验期间均显示有利尿作用，且有统计学差异。
车前草总苷的利尿作用(n＝24)
| 组别 | 剂量mg/Kg | 给药后不同时间累计尿量(ml)(X±SD) | ||||
| 1h | 2h | 3h | 4h | 6h | ||
| 对照总苷低总苷高 | 3060 | 2.68±1.093.18±0.743.64±0.41** | 4.13±0.574.47±1.185.05±0.71** | 4.97±0.515.27±1.245.44±0.66* | 5.56±0.915.98±1.356.46±0.66** | 6.77±1.247.17±1.437.48±0.76* |
注：T检验，与对照组比较：*p＜0.05，**p＜0.01
实例3 车前草总苷的免疫调节作用
方法：SRBC定量溶血测定法观察车前草总苷对小鼠抗体生成的影响。
用BALB/C小鼠，雌性，按体重均匀分为5组；受试药物按剂量设40、20、10mg/Kg体重三个剂量组，经口给予车前草总苷溶液；空白对照组经口给予同体积的蒸馏水。每天给药一次，连续给药9天。以腹腔注射15mg/Kg环磷酰胺为阳性对照组，在试验的第6～8天给药，每天一次。在给药的第六天全部小鼠腹腔注射5％SRBC以致敏，每只0.2ml(相当于3×108SRBC)致敏后96小时，放血处死小鼠，取脾。用RPMI1640培养液按15mg脾重/ml制成脾细胞悬液，依次在试管中加入等容量三脾细胞悬液、0.2％SRBC和1：10豚鼠血清，混匀，37℃水浴温育1小时，离心，取上清液，于分光光度计测定吸光度，以OD值表示抗体生成水平。车前草总苷10～20mg/Kg经口给药可明显抑制致敏小鼠IgM抗体生成，对体液免疫呈较强的抑制作用。
车前草总苷对小鼠抗体生成的影响(X±SD)
| 剂量mg/Kg | 动物数只 | 抗体溶血值(OD) | 抑制率(％) | |
| 空白对照CY车前草总苷高车前草总苷中车前草总苷低 | 1520105 | 1210101010 | 1.006±0.1690.545±0.168**0.662±0.189**0.730±0.170**0.892±0.178 | 45.834.227.411.3 |
T检验*p＜0.05 **p＜0.01
实例4 车前草总苷对大鼠C-BSA肾炎的作用观察
方法1：将阳离子化牛血清白蛋白(C-BSA)1mg，加入0.5mlD到PBS中，再加0.5ml不完全佐剂充分混匀，研磨成乳剂。在大鼠双侧腋下、腹股沟作多点皮下注射进行预免疫。预免疫一周后正式免疫，每只大鼠尾静脉注射C-BSA2.5mg，每周三次，四周后加量到4mg/只，直到试验结束。
在正式免疫四周后，开始给药，每日一次，连续给药四周。设车前草总苷高、中、低(分别为40、20、10mg/Kg)三个剂量组，经口给药；环磷酰胺(CY)10mg/Kg，腹腔注射给药，为阳性对照组。模型组经口给蒸馏水，另设空白对照组，经口给蒸馏水。观测药前、给药后1、2.5、4周24小时尿旦白总量，车前草总苷20～40mg/Kg，经口给药四周，对大鼠C-BSA肾炎有明显的治疗作用，其作用强度与腹腔注射10mg/Kg环磷酰胺的作用相似。
24小时尿蛋白量的变化(X±SD)
| 组别 | 剂量mg/Kg | 尿蛋白(mg/24h) | |||
| 给药前 | 给药10天 | 给药20天 | 给药30天 | ||
| 空白模型CY四味肾炎片车前草总苷高车前草总苷中车前草总苷低 | 81000502512.5 | 10.7±2.8(7)216.2±172.5(14)219.0±174.7(14)219.2±190.8(14)217.5±185.5(14)218.9±181.2(14)216.6±182.2(14) | 13.5±3.0(7)460.6±195.4(13)293.2±131.9(12)*501.5±177.5(13)427.3±213.0(14)442.7±242.0(12)431.0±220.8(12) | 13.1±3.4(7)454.5±220.1(13)283.0±156.5(11)*443.5±166.4(13)374.7±191.5(14)396.0±160.6(12)405.0±200.8(12) | 12.4±3.4(7)427.2±178.8(12)210.9±139.1(11)**380.4±159.2(12)246.9±114.8(14)**272.4±124.7(12)*333.9±227.8(12) |
注：T检验与模型组比较，*p＜0.05 **p＜0.01；()内数字为动物数。
实例5 车前草总苷对兔IgG加速型小鼠肾毒血清肾炎的作用
在无菌条件下，取小鼠肾皮质剪碎，研磨并过200目钢丝网，1500rpm离心10分钟，取沉淀物，加福氏完全佐剂，充分研磨使成均匀的含10％肾组织的乳剂，用此乳剂免疫兔，1ml/只，皮下多点注射，每周一次，共六次。第一次免疫要加入卡介苗原浆，浓度为4mg/ml乳剂。末次注射后5天，兔颈动脉放血，离心得血清，经灭活补体及BALB/C小鼠血球吸收后再离心得肾毒血清。
小鼠先腹腔注射兔IgG0.5mg(与0.25ml福氏完全佐剂充分混匀)，4天后尾静脉注射肾毒血清0.08ml/只，注射后5天，测小鼠尿蛋白及血浆白蛋白含量，按其测定值均匀6组，设模型对照组，阳性对照组，给环磷酰胺(CY)10mg/kg(i.p)，空白对照组，给蒸馏水(p.o)，给药组设四个剂量组，分别给车前草总苷80、40、20mg/kg(p.o)。连续给药21天。在给药后的第14天、21天测尿蛋白。车前草总苷40～80mg/kg口服3周，对兔IgG加速型小鼠肾毒血清肾炎有明显的治疗作用，其作用强度与CY10mg/kg(i.p)相似；20mg/kg剂量组的作用较弱。显示有一定的量效关系。22天放血处死，取小鼠肾作病理检查，常规固定，包埋，切片，P.A.S及Masson三色染色，光镜下观察，模型组动物大多有肾小球毛细管基底膜明显增厚，Mas-son染色标本可见部分肾小球毛细管呈纤维素样坏死， 部分肾小球囊壁细胞增生，形成新月体，严重者肾小球与囊粘连，有纤维化和萎缩现象，部分肾小球管腔有蛋白管型存在。与模型组比，CY组及车前草总苷高、中、低剂量组肾脏病变较轻，肾小管腔内蛋白管型数量减少。小鼠尿蛋白的变化(X±SD)
| 组别 | 剂量mg/kg | 尿蛋白(mg/dl) | ||
| 给药前 | 给药2周 | 给药3周 | ||
| 空白模型CY保肾康车前草总苷高车前草总苷中车前草总苷低 | 10100804020 | 24.0±9.7312±76(17)306±81(16)309±80(16)312±76(17)314±74(17)309±80(17) | 24.0±9.7277±44(13)202±76(12)*259±69(14)194±85(14)**191±91(15)**221±74(14)* | 26.0±8.4259±38(11)198±64(11)*244±76(14)183±75(14)**156±96(14)**188±85(13)* |
注：T检验，与模型组相比较*p＜0.05 **p＜0.01；()内数字代表动物数。
实例6.车前草总苷胶囊的制备
将100g车前草总苷加入适量乳糖，结晶纤维素，聚乙二醇3000，羧甲基淀粉钠，干压制粒后，加硬脂酸镁适量，分装成1000粒，即得。每粒含acteoside 30mg。
实例6.车前草总苷片剂的制备
100g的车前草总苷，加入适量乳糖，淀粉，以60～80％乙醇为粘合剂制粒，干燥，整粒，加适量硬脂酸镁，压制成1000片，包薄膜衣，每片含acteoside 30mg。
实例7.车前草总苷颗粒剂的制备
100g的车前草总苷，加入适量乳糖，糊精，糖粉，以60～80％乙醇为粘合剂制粒，干燥，整粒，分装成1000袋，每袋含acteoside 30mg。
Claims (9)
1、车前草总苷及其制备方法，其特征在于药材用水、醇或酸性水、酸性醇提取，提取液回收溶剂和/或经大孔树脂处理等方法制备的车前草总苷。
2、按照权力要求1所述的车前草总苷中含acteoside在10％～80％范围内。
3、按照权力要求2所述的acteoside在药品或药物制剂中的含量为10～70％，或总苷在药品或制剂中的人日用剂量为50～2000mg。
4、按照权力要求1所述的提取用醇是指甲醇或乙醇或含水甲醇或含水乙醇；酸性醇是指提取用的甲醇或乙醇或含水甲醇或含水乙醇中加有0.5％～10％的甲酸或乙酸或盐酸或磷酸等有机酸或无机酸的混合溶剂。
5、按照权力要求1所述的大孔树脂是指大孔树脂D101或HP-20或SP825或HP2MG等以苯乙烯或甲基丙稀酸酯为骨架的大孔树脂。
6、按照权力要求1、2、3所述的车前草总苷或以车前草总苷为药品原料制备的药物制剂对慢性肾小球肾炎有治疗作用。
7、按照权力要求1、2、3所述的车前草总苷或以车前草总苷为药品原料制备的药物制剂有利尿作用。
8、按照权力要求1、2、3所述的车前草总苷或以车前草总苷为药品原料制备的药物制剂有免疫抑制作用。
9、按照权力要求1、2、3所述的车前草总苷或以车前草总苷为药品原料制备的药物制剂对对大鼠C-BSA肾炎及兔IgG加速型小鼠肾毒血清肾炎有治疗作用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021252548A CN1319981C (zh) | 2002-07-19 | 2002-07-19 | 车前草总苷的制备工艺及其在医药中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021252548A CN1319981C (zh) | 2002-07-19 | 2002-07-19 | 车前草总苷的制备工艺及其在医药中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1513862A true CN1513862A (zh) | 2004-07-21 |
| CN1319981C CN1319981C (zh) | 2007-06-06 |
Family
ID=34231152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021252548A Expired - Fee Related CN1319981C (zh) | 2002-07-19 | 2002-07-19 | 车前草总苷的制备工艺及其在医药中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1319981C (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225095A (zh) * | 2011-06-23 | 2011-10-26 | 上海中医药大学 | 一种车前子有效部位及其制备方法和应用 |
| CN106034521A (zh) * | 2016-05-31 | 2016-10-26 | 山东胜伟园林科技有限公司 | 一种使用氨基酸营养液的膜下滴灌方法及其在盐碱地中种植甜高粱的应用 |
| CN106579070A (zh) * | 2016-09-30 | 2017-04-26 | 南陵县石斛产业协会 | 一种车前草风味鳡鱼保健罐头 |
| CN112586515A (zh) * | 2020-12-22 | 2021-04-02 | 长江绿银(无锡)科技有限公司 | 一种北美车前中提取化感物质和苯乙醇苷类化合物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02200620A (ja) * | 1989-01-27 | 1990-08-08 | Inahata Koryo Kk | 消臭剤 |
| JPH08301730A (ja) * | 1995-05-01 | 1996-11-19 | Nonogawa Shoji Kk | 育毛剤 |
| US5716635A (en) * | 1995-07-19 | 1998-02-10 | M. E. Cody Products, Inc. | Plantago major transdermal patch for use in treating a tobacco or nicotine habit |
| US6309675B1 (en) * | 1999-07-21 | 2001-10-30 | Nancy Laning Sobczak | Therapeutic composition including plantain and aloe vera for treatment of arthritis and other afflictions |
| WO2001034169A1 (de) * | 1999-11-11 | 2001-05-17 | Dietrich Paper | Verwendung eines extraktes aus plantago lanceolata |
-
2002
- 2002-07-19 CN CNB021252548A patent/CN1319981C/zh not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225095A (zh) * | 2011-06-23 | 2011-10-26 | 上海中医药大学 | 一种车前子有效部位及其制备方法和应用 |
| CN106034521A (zh) * | 2016-05-31 | 2016-10-26 | 山东胜伟园林科技有限公司 | 一种使用氨基酸营养液的膜下滴灌方法及其在盐碱地中种植甜高粱的应用 |
| CN106579070A (zh) * | 2016-09-30 | 2017-04-26 | 南陵县石斛产业协会 | 一种车前草风味鳡鱼保健罐头 |
| CN112586515A (zh) * | 2020-12-22 | 2021-04-02 | 长江绿银(无锡)科技有限公司 | 一种北美车前中提取化感物质和苯乙醇苷类化合物的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1319981C (zh) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526165B (zh) | 一种红景天有效部位、其制备方法、其药物组合物及用途 | |
| EP2581087B1 (en) | Composition containing iridoids and uses thereof | |
| CN112716989B (zh) | 一种芹菜籽提取物及其制备方法与应用 | |
| US8945633B2 (en) | Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction | |
| CN1931228A (zh) | 金钱草总黄酮提取物及其制备方法 | |
| JPH01157995A (ja) | 鎮痛−抗炎症活性を有するガングリオシドの内部エステル | |
| CN100500160C (zh) | 含淫羊藿有效成分的药物组合物及其用途 | |
| CN1382478A (zh) | 桑枝提取物及其提取方法和新用途 | |
| CN104224863B (zh) | 金钱草总黄酮在制备治疗高尿酸血症药物中的应用 | |
| CN1319981C (zh) | 车前草总苷的制备工艺及其在医药中的应用 | |
| JPH0832632B2 (ja) | 尿素窒素代謝改善剤 | |
| CN107158050A (zh) | 圆锥绣球总香豆素苷、其制备方法及其组合物与用途 | |
| US8221801B2 (en) | Antiviral product | |
| RU2651750C2 (ru) | Применение экстракта albizzia chinensis для получения лекарственного средства для лечения язвы желудка | |
| WO2022151978A1 (zh) | 一种治疗泌尿系统结石症相关疾病的药物及其制备方法 | |
| CN1141101C (zh) | 治疗乙肝的药物及其制备方法 | |
| CN1283462A (zh) | 黄芪甲苷在制备药物组合物中的应用 | |
| CN112807397A (zh) | 一种治疗慢性肾炎的中药组合物及其制备方法和应用 | |
| CN101974012B (zh) | 一种具有药用活性的新化合物灯盏细辛酸乙酯 | |
| CN102018740B (zh) | 含有向日葵叶提取物的药物组合物及其用途 | |
| CN114452293B (zh) | 牡荆素木糖苷的降尿酸用途及其制备方法 | |
| CN114767695B (zh) | 水葱内酯的提取方法及其应用 | |
| CN1148193C (zh) | 低聚寡糖在抗应激脑损伤中的用途 | |
| CN1119156C (zh) | 仙草藤胶囊及其制备方法 | |
| JP2000302784A (ja) | アポシニン類およびそれらを含有する肝疾患予防・治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: PEKING UNIVERSITY Free format text: FORMER NAME OR ADDRESS: GUO XULIN; WANG TIEJUN |
|
| CP03 | Change of name, title or address |
Address after: 100083 Peking University Health Science Center, Haidian District, Xueyuan Road, 38, Beijing Patentee after: Peking University Address before: 100083 No. 38, Haidian District, Beijing, Xueyuan Road Co-patentee before: Wang Tiejun Patentee before: Guo Xulin |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070606 Termination date: 20160719 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |